Format

Send to

Choose Destination
JAMA Psychiatry. 2017 Jun 1;74(6):579-588. doi: 10.1001/jamapsychiatry.2017.0724.

US Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws: 1991-1992 to 2012-2013.

Author information

1
Department of Psychiatry, Columbia University Medical Center, New York, New York2New York State Psychiatric Institute, New York3Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.
2
Department of Psychiatry, Columbia University Medical Center, New York, New York2New York State Psychiatric Institute, New York.
3
Department of Emergency Medicine, University of California, Davis, Sacramento.
4
Department of Psychiatry, Columbia University Medical Center, New York, New York3Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.
5
New York State Psychiatric Institute, New York.
6
School of Public Health, Boston University, Boston, Massachusetts.
7
Department of Psychiatry, Columbia University Medical Center, New York, New York2New York State Psychiatric Institute, New York6Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York.

Abstract

Importance:

Over the last 25 years, illicit cannabis use and cannabis use disorders have increased among US adults, and 28 states have passed medical marijuana laws (MML). Little is known about MML and adult illicit cannabis use or cannabis use disorders considered over time.

Objective:

To present national data on state MML and degree of change in the prevalence of cannabis use and disorders.

Design, Participants, and Setting:

Differences in the degree of change between those living in MML states and other states were examined using 3 cross-sectional US adult surveys: the National Longitudinal Alcohol Epidemiologic Survey (NLAES; 1991-1992), the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC; 2001-2002), and the National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III; 2012-2013). Early-MML states passed MML between NLAES and NESARC ("earlier period"). Late-MML states passed MML between NESARC and NESARC-III ("later period").

Main Outcomes and Measures:

Past-year illicit cannabis use and DSM-IV cannabis use disorder.

Results:

Overall, from 1991-1992 to 2012-2013, illicit cannabis use increased significantly more in states that passed MML than in other states (1.4-percentage point more; SE, 0.5; P = .004), as did cannabis use disorders (0.7-percentage point more; SE, 0.3; P = .03). In the earlier period, illicit cannabis use and disorders decreased similarly in non-MML states and in California (where prevalence was much higher to start with). In contrast, in remaining early-MML states, the prevalence of use and disorders increased. Remaining early-MML and non-MML states differed significantly for use (by 2.5 percentage points; SE, 0.9; P = .004) and disorder (1.1 percentage points; SE, 0.5; P = .02). In the later period, illicit use increased by the following percentage points: never-MML states, 3.5 (SE, 0.5); California, 5.3 (SE, 1.0); Colorado, 7.0 (SE, 1.6); other early-MML states, 2.6 (SE, 0.9); and late-MML states, 5.1 (SE, 0.8). Compared with never-MML states, increases in use were significantly greater in late-MML states (1.6-percentage point more; SE, 0.6; P = .01), California (1.8-percentage point more; SE, 0.9; P = .04), and Colorado (3.5-percentage point more; SE, 1.5; P = .03). Increases in cannabis use disorder, which was less prevalent, were smaller but followed similar patterns descriptively, with change greater than never-MML states in California (1.0-percentage point more; SE, 0.5; P = .06) and Colorado (1.6-percentage point more; SE, 0.8; P = .04).

Conclusions and Relevance:

Medical marijuana laws appear to have contributed to increased prevalence of illicit cannabis use and cannabis use disorders. State-specific policy changes may also have played a role. While medical marijuana may help some, cannabis-related health consequences associated with changes in state marijuana laws should receive consideration by health care professionals and the public.

PMID:
28445557
PMCID:
PMC5539836
DOI:
10.1001/jamapsychiatry.2017.0724
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center